Adaptive Biotechnologies reports Q4 EPS (23c), consensus (24c)

Reports Q4 revenue $47.46M, consensus $46.05M. “2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “With strong momentum heading into 2025, we are focused on achieving profitability in MRD, advancing our therapeutics pipeline in Immune Medicine, and maintaining a durable cash position to support sustainable, long-term growth.”